Market Overview

Newron Pharmaceuticals to Present at H.C. Wainwright Annual Healthcare Conference

Share:

Newron
Pharmaceuticals S.p.A.
("Newron") (SIX: NWRN), a biopharmaceutical
company focused on the development of novel therapies for patients with
diseases of the central and peripheral nervous system, today announced
that Stefan Weber, CEO, will present at the H.C. Wainwright Annual
Healthcare Conference in New York, NY, on Wednesday, September 05, 2018
at 5:30 p.m. ET.

About Newron Pharmaceuticals

Newron (SIX: NWRN) is a biopharmaceutical company focused on the
development of novel therapies for patients with diseases of the central
and peripheral nervous system. The Company is headquartered in Bresso
near Milan, Italy. Xadago® (safinamide) has received marketing
authorization for the treatment of Parkinson's disease in the European
Union, Switzerland and the USA, and is commercialized by Newron's
Partner Zambon. US WorldMeds holds the commercialization rights in the
USA. Meiji Seika has the rights to develop and commercialize the
compound in Japan and other key Asian territories. In addition to
Xadago® for Parkinson's disease, Newron has a strong pipeline of
promising treatments for rare disease patients at various stages of
clinical development, including sarizotan for patients with Rett
syndrome and ralfinamide for patients with specific rare pain
indications. Newron is also developing Evenamide as the potential first
add-on therapy for the treatment of patients with positive symptoms of
schizophrenia. For more information, please visit: www.newron.com

View Comments and Join the Discussion!